<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02143778</url>
  </required_header>
  <id_info>
    <org_study_id>CSPH-EX-4014</org_study_id>
    <secondary_id>2014-002037-59</secondary_id>
    <nct_id>NCT02143778</nct_id>
  </id_info>
  <brief_title>Assessing Portal Hypertension With Methacetin Breath Test</brief_title>
  <official_title>Clinical Study of the BreathID® LF System to Train the Algorithm for the ¹³C-Methacetin Breath Test (MBT) in Assessment of Portal Hypertension in Patients With Compensated Liver Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be used to train an algorithm using Methacetin breath test (MBT) measures and
      to select a cut-off to determine presence or absence of Clinically Significant Portal
      Hypertension (CSPH) as defined by Hepatic Venous Gradient Pressure (HVPG) ≥ 10mmHg,
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The portal pressure leaving the liver is measured by using a balloon catheter before and
      after a wedge. The difference of the pressure between the wedge and the free is the hepatic
      venous pressure gradient. Methacetin breath test is hypothesized to also identify CSPH and
      the agreement to the reference standard (HVPG) will be assessed in this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2014</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CSPH (Clinically Significant Portal Hypertension)</measure>
    <time_frame>1 hour</time_frame>
    <description>Clinically significant portal hypertension is defined as Hepatic Venous Pressure Gradient (HVPG)&gt;=10mmHg, whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify CSPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hepatic Venous Pressure Gradient (HVPG)&gt;=12; Severe Portal Hypertension (SPH)</measure>
    <time_frame>1 hour</time_frame>
    <description>Hepatic Venous Pressure Gradient greater than 12 (SPH) is an indicator of bleeding varices. whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify SPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">246</enrollment>
  <condition>Patients With Compensated Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Compensated cirrhotic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Methacetin Breath Test</intervention_name>
    <description>13C labelled methacetin solution for breath test monitoring</description>
    <arm_group_label>Compensated cirrhotic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men or women (&gt;18 years of age)

          -  Known chronic liver disease with cirrhosis

          -  Europe: Indicated to undergo HVPG testing

          -  US: Consented for HVPG

          -  For patients treated with beta blockers: They have to be on a stable dose for at least
             6 weeks prior to any study related tasks

          -  For patients who stopped their treatment with beta blockers: Their last dose should be
             at least 6 weeks prior to any study related tasks

        Exclusion Criteria:

          -  Decompensated cirrhosis as clinically defined by the presence of ascites, hepatic
             encephalopathy, variceal bleeding or hepatorenal syndrome

          -  Renal failure (creatinine &gt; 2.5 mg/dl)

          -  Known acute renal tubular disease Known hypotension (Systolic Pressure &lt;100mmHg)

          -  Hypocoagulablity defined as PT &gt;6 and INR &gt;2.3.

          -  Congestive heart failure (assessed clinically as NIHA &gt;2)

          -  Known pulmonary hypertension (right ventricular systolic pressure &gt; 45 mm Hg)

          -  Uncontrolled diabetes mellitus (HBA1C &gt;9.5gr%)

          -  Concurrent prednisone or immunosuppressive treatment, if therapy and/or response to
             treatment are not stable for at least 3 months.

          -  Documented or suspected hepatocellular carcinoma

          -  Gastric bypass surgery or extensive small bowel resection

          -  Total parenteral nutrition

          -  Any organ transplant recipient

          -  Pregnant or breast feeding

          -  Allergy to acetaminophen and/or other related medications

          -  Documented drug-related concurrent hepatotoxicity or drug-related silent steatosis or
             drug-related fibrosis (e.g. amiodarone, methotrexate and tamoxifen)

          -  Uncontrolled malabsorption or diarrhea

          -  Documented non-cirrhotic PHT, partial / complete portal venous occlusion, hepatic
             venous occlusion, previous PHT surgery, or placement of a transjugular intrahepatic
             portosystemic shunt (TIPS)

          -  Primary or secondary biliary cirrhosis, primary or secondary sclerosing cholangitis,
             hepatic sarcoidosis, or other cholestatic disorders

          -  Subjects unable to perform the MBT within 7 days of HVPG procedure.

          -  Subject should not have taken any of the following for at least 48 hours prior to the
             breath test: Acyclovir , allopurinol, amiodarone, carbamazepine, cimetidine,
             ciprofloxacin, daidzein, (herbal) disulfiram, echinacea, enoxacin, famotidine,
             fluvoxamine, methoxsalen, mexiletine, montelukast, norfloxacin, phenylpropanolamine,
             phenytoin, propafenone, rifampin, terbinafine, ticlopidine, thiabendazole, verapamil,
             zileuton or oral contraceptives or any medication that might interfere with Methacetin
             metabolism or might affect CYP 1A2

          -  Subject should not have taken amiodarone or statins within the last 30 days prior to
             the breath test or HVPG procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Carlos Garcia Pagan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Connecticut HealthCare System</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Purpan</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>(University of Barcelona) Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>May 18, 2014</study_first_submitted>
  <study_first_submitted_qc>May 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2014</study_first_posted>
  <results_first_submitted>August 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 27, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 19, 2019</results_first_posted>
  <last_update_submitted>October 10, 2019</last_update_submitted>
  <last_update_submitted_qc>October 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MBT</keyword>
  <keyword>CSPH</keyword>
  <keyword>HVPG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 21, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/78/NCT02143778/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Compensated Cirrhotic Patients</title>
          <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
Methacetin Breath Test: 13C labelled methacetin solution for breath test monitoring</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="243"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Device malfunction</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Compensated Cirrhotic Patients</title>
          <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
Methacetin Breath Test: 13C labelled methacetin solution for breath test monitoring</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="246"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.6" spread="9.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="242"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>CSPH (Clinically Significant Portal Hypertension)</title>
        <description>Clinically significant portal hypertension is defined as Hepatic Venous Pressure Gradient (HVPG)&gt;=10mmHg, whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify CSPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
        <time_frame>1 hour</time_frame>
        <population>Compensated cirrhotic patients with CSPH based on breath test compared to CSPH from HVPG (reference standard)</population>
        <group_list>
          <group group_id="O1">
            <title>Compensated Cirrhotic Patients With CSPH</title>
            <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
Methacetin Breath Test: 13C labelled methacetin solution for breath test monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>CSPH (Clinically Significant Portal Hypertension)</title>
          <description>Clinically significant portal hypertension is defined as Hepatic Venous Pressure Gradient (HVPG)&gt;=10mmHg, whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify CSPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
          <population>Compensated cirrhotic patients with CSPH based on breath test compared to CSPH from HVPG (reference standard)</population>
          <units>percentage of agreement</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.82" lower_limit="74.22" upper_limit="89.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hepatic Venous Pressure Gradient (HVPG)&gt;=12; Severe Portal Hypertension (SPH)</title>
        <description>Hepatic Venous Pressure Gradient greater than 12 (SPH) is an indicator of bleeding varices. whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify SPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
        <time_frame>1 hour</time_frame>
        <population>Compensated cirrhotic Patients with Severe Portal Hypertension based on MBT compared to HVPG (reference standard)</population>
        <group_list>
          <group group_id="O1">
            <title>Compensated Cirrhotic Patients With SPH</title>
            <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis with severe portal hypertension.
Methacetin Breath Test: 13C labelled methacetin solution for breath test monitoring</description>
          </group>
        </group_list>
        <measure>
          <title>Hepatic Venous Pressure Gradient (HVPG)&gt;=12; Severe Portal Hypertension (SPH)</title>
          <description>Hepatic Venous Pressure Gradient greater than 12 (SPH) is an indicator of bleeding varices. whereby the portal pressure leaving the liver is measured by using a balloon catheter before and after a wedge. The difference of the pressure between the wedge and the free is the hepatic venous pressure gradient. Methacetin breath test is hypothesized to also identify SPH and the agreement to the reference standard (HVPG) will be assessed in this study.</description>
          <population>Compensated cirrhotic Patients with Severe Portal Hypertension based on MBT compared to HVPG (reference standard)</population>
          <units>percentage of agreement</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.39" lower_limit="66.58" upper_limit="86.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The Methacetin used in the breath test has a high extraction rate and is removed after less than 48 hours. Follow up was done for 48 hours after breath test. After 30 days another follow up phone call was made.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Compensated Cirrhotic Patients</title>
          <description>A methacetin breath test will be performed on patients who are undergoing the HVPG procedure due to their clinical indication of compensated cirrhosis.
Methacetin Breath Test: 13C labelled methacetin solution for breath test monitoring</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="246"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Severe Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>UTI</sub_title>
                <description>Urinary Tract Infection</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="246"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Manager</name_or_title>
      <organization>Exalenz Bisocience</organization>
      <phone>97289737500</phone>
      <email>avrahamh@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

